The novel ribonucleotide reductase inhibitor COH29 inhibits DNA repair in vitros

Mei Chuan Chen, Bingsen Zhou, Keqiang Zhang, Yate Ching Yuan, Frank Un, Shuya Hu, Chih Ming Chou, Chun Han Chen, Jun Wu, Yan Wang, Xiyong Liu, D. Lynne Smith, Hongzhi Li, Zheng Liu, Charles D. Warden, Leila Su, Linda H. Malkas, Young Min Chung, Mickey C T Hu, Yun Yen

研究成果: 雜誌貢獻文章

11 引文 (Scopus)

摘要

COH29 [N-(4-(3,4-dihydroxyphenyl)-5-phenylthiazol-2-yl)-3,4- dihydroxybenzamide], a novel antimetabolite drug developed at City of Hope Cancer Center, has anticancer activity that stems primarily from the inhibition of human ribonucleotide reductase (RNR). This key enzyme in deoxyribonucleotide biosynthesis is the target of established clinical agents such as hydroxyurea and gemcitabine because of its critical role in DNA replication and repair. Herein we report that BRCA-1-defective human breast cancer cells are more sensitive than wild-type BRCA-1 counterparts to COH29 in vitro and in vivo. Microarray gene expression profiling showed that COH29 reduces the expression of DNA repair pathway genes, suggesting that COH29 interferes with these pathways. It is well established that BRCA1 plays a role in DNA damage repair, especially homologous recombination (HR) repair, to maintain genome integrity. In BRCA1-defective HCC1937 breast cancer cells, COH29 induced more double-strand breaks (DSBs) and DNA-damage response than in HCC1937 + BRCA1 cells. By EJ5- and DR-green fluorescent protein (GFP) reporter assay, we found that COH29 could inhibit nonhomologous end joining (NHEJ) efficiency and that no HR activity was detected in HCC1937 cells, suggesting that repression of the NHEJ repair pathway may be involved in COH29-induced DSBs in BRCA1-deficient HCC1937 cells. Furthermore, we observed an accumulation of nuclear Rad51 foci in COH29-treated HCC1937 + BRCA1 cells, suggesting that BRCA1 plays a crucial role in repairing and recovering drug-induced DNA damage by recruiting Rad51 to damage sites. In summary, we describe here additional biologic effects of the RNR inhibitor COH29 that potentially strengthen its use as an anticancer agent.
原文英語
頁(從 - 到)996-1005
頁數10
期刊Molecular Pharmacology
87
發行號6
DOIs
出版狀態已發佈 - 六月 1 2015

指紋

Ribonucleotide Reductases
DNA Repair
DNA Damage
gemcitabine
Deoxyribonucleotides
Breast Neoplasms
Recombinational DNA Repair
Antimetabolites
Hydroxyurea
Homologous Recombination
Gene Expression Profiling
Green Fluorescent Proteins
DNA Replication
Pharmaceutical Preparations
Antineoplastic Agents
Genome
Enzymes
Genes
Neoplasms

ASJC Scopus subject areas

  • Pharmacology
  • Molecular Medicine

引用此文

The novel ribonucleotide reductase inhibitor COH29 inhibits DNA repair in vitros. / Chen, Mei Chuan; Zhou, Bingsen; Zhang, Keqiang; Yuan, Yate Ching; Un, Frank; Hu, Shuya; Chou, Chih Ming; Chen, Chun Han; Wu, Jun; Wang, Yan; Liu, Xiyong; Smith, D. Lynne; Li, Hongzhi; Liu, Zheng; Warden, Charles D.; Su, Leila; Malkas, Linda H.; Chung, Young Min; Hu, Mickey C T; Yen, Yun.

於: Molecular Pharmacology, 卷 87, 編號 6, 01.06.2015, p. 996-1005.

研究成果: 雜誌貢獻文章

Chen, MC, Zhou, B, Zhang, K, Yuan, YC, Un, F, Hu, S, Chou, CM, Chen, CH, Wu, J, Wang, Y, Liu, X, Smith, DL, Li, H, Liu, Z, Warden, CD, Su, L, Malkas, LH, Chung, YM, Hu, MCT & Yen, Y 2015, 'The novel ribonucleotide reductase inhibitor COH29 inhibits DNA repair in vitros', Molecular Pharmacology, 卷 87, 編號 6, 頁 996-1005. https://doi.org/10.1124/mol.114.094987
Chen, Mei Chuan ; Zhou, Bingsen ; Zhang, Keqiang ; Yuan, Yate Ching ; Un, Frank ; Hu, Shuya ; Chou, Chih Ming ; Chen, Chun Han ; Wu, Jun ; Wang, Yan ; Liu, Xiyong ; Smith, D. Lynne ; Li, Hongzhi ; Liu, Zheng ; Warden, Charles D. ; Su, Leila ; Malkas, Linda H. ; Chung, Young Min ; Hu, Mickey C T ; Yen, Yun. / The novel ribonucleotide reductase inhibitor COH29 inhibits DNA repair in vitros. 於: Molecular Pharmacology. 2015 ; 卷 87, 編號 6. 頁 996-1005.
@article{757c5b0505754a6ebee81b417d64981c,
title = "The novel ribonucleotide reductase inhibitor COH29 inhibits DNA repair in vitros",
abstract = "COH29 [N-(4-(3,4-dihydroxyphenyl)-5-phenylthiazol-2-yl)-3,4- dihydroxybenzamide], a novel antimetabolite drug developed at City of Hope Cancer Center, has anticancer activity that stems primarily from the inhibition of human ribonucleotide reductase (RNR). This key enzyme in deoxyribonucleotide biosynthesis is the target of established clinical agents such as hydroxyurea and gemcitabine because of its critical role in DNA replication and repair. Herein we report that BRCA-1-defective human breast cancer cells are more sensitive than wild-type BRCA-1 counterparts to COH29 in vitro and in vivo. Microarray gene expression profiling showed that COH29 reduces the expression of DNA repair pathway genes, suggesting that COH29 interferes with these pathways. It is well established that BRCA1 plays a role in DNA damage repair, especially homologous recombination (HR) repair, to maintain genome integrity. In BRCA1-defective HCC1937 breast cancer cells, COH29 induced more double-strand breaks (DSBs) and DNA-damage response than in HCC1937 + BRCA1 cells. By EJ5- and DR-green fluorescent protein (GFP) reporter assay, we found that COH29 could inhibit nonhomologous end joining (NHEJ) efficiency and that no HR activity was detected in HCC1937 cells, suggesting that repression of the NHEJ repair pathway may be involved in COH29-induced DSBs in BRCA1-deficient HCC1937 cells. Furthermore, we observed an accumulation of nuclear Rad51 foci in COH29-treated HCC1937 + BRCA1 cells, suggesting that BRCA1 plays a crucial role in repairing and recovering drug-induced DNA damage by recruiting Rad51 to damage sites. In summary, we describe here additional biologic effects of the RNR inhibitor COH29 that potentially strengthen its use as an anticancer agent.",
author = "Chen, {Mei Chuan} and Bingsen Zhou and Keqiang Zhang and Yuan, {Yate Ching} and Frank Un and Shuya Hu and Chou, {Chih Ming} and Chen, {Chun Han} and Jun Wu and Yan Wang and Xiyong Liu and Smith, {D. Lynne} and Hongzhi Li and Zheng Liu and Warden, {Charles D.} and Leila Su and Malkas, {Linda H.} and Chung, {Young Min} and Hu, {Mickey C T} and Yun Yen",
year = "2015",
month = "6",
day = "1",
doi = "10.1124/mol.114.094987",
language = "English",
volume = "87",
pages = "996--1005",
journal = "Molecular Pharmacology",
issn = "0026-895X",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "6",

}

TY - JOUR

T1 - The novel ribonucleotide reductase inhibitor COH29 inhibits DNA repair in vitros

AU - Chen, Mei Chuan

AU - Zhou, Bingsen

AU - Zhang, Keqiang

AU - Yuan, Yate Ching

AU - Un, Frank

AU - Hu, Shuya

AU - Chou, Chih Ming

AU - Chen, Chun Han

AU - Wu, Jun

AU - Wang, Yan

AU - Liu, Xiyong

AU - Smith, D. Lynne

AU - Li, Hongzhi

AU - Liu, Zheng

AU - Warden, Charles D.

AU - Su, Leila

AU - Malkas, Linda H.

AU - Chung, Young Min

AU - Hu, Mickey C T

AU - Yen, Yun

PY - 2015/6/1

Y1 - 2015/6/1

N2 - COH29 [N-(4-(3,4-dihydroxyphenyl)-5-phenylthiazol-2-yl)-3,4- dihydroxybenzamide], a novel antimetabolite drug developed at City of Hope Cancer Center, has anticancer activity that stems primarily from the inhibition of human ribonucleotide reductase (RNR). This key enzyme in deoxyribonucleotide biosynthesis is the target of established clinical agents such as hydroxyurea and gemcitabine because of its critical role in DNA replication and repair. Herein we report that BRCA-1-defective human breast cancer cells are more sensitive than wild-type BRCA-1 counterparts to COH29 in vitro and in vivo. Microarray gene expression profiling showed that COH29 reduces the expression of DNA repair pathway genes, suggesting that COH29 interferes with these pathways. It is well established that BRCA1 plays a role in DNA damage repair, especially homologous recombination (HR) repair, to maintain genome integrity. In BRCA1-defective HCC1937 breast cancer cells, COH29 induced more double-strand breaks (DSBs) and DNA-damage response than in HCC1937 + BRCA1 cells. By EJ5- and DR-green fluorescent protein (GFP) reporter assay, we found that COH29 could inhibit nonhomologous end joining (NHEJ) efficiency and that no HR activity was detected in HCC1937 cells, suggesting that repression of the NHEJ repair pathway may be involved in COH29-induced DSBs in BRCA1-deficient HCC1937 cells. Furthermore, we observed an accumulation of nuclear Rad51 foci in COH29-treated HCC1937 + BRCA1 cells, suggesting that BRCA1 plays a crucial role in repairing and recovering drug-induced DNA damage by recruiting Rad51 to damage sites. In summary, we describe here additional biologic effects of the RNR inhibitor COH29 that potentially strengthen its use as an anticancer agent.

AB - COH29 [N-(4-(3,4-dihydroxyphenyl)-5-phenylthiazol-2-yl)-3,4- dihydroxybenzamide], a novel antimetabolite drug developed at City of Hope Cancer Center, has anticancer activity that stems primarily from the inhibition of human ribonucleotide reductase (RNR). This key enzyme in deoxyribonucleotide biosynthesis is the target of established clinical agents such as hydroxyurea and gemcitabine because of its critical role in DNA replication and repair. Herein we report that BRCA-1-defective human breast cancer cells are more sensitive than wild-type BRCA-1 counterparts to COH29 in vitro and in vivo. Microarray gene expression profiling showed that COH29 reduces the expression of DNA repair pathway genes, suggesting that COH29 interferes with these pathways. It is well established that BRCA1 plays a role in DNA damage repair, especially homologous recombination (HR) repair, to maintain genome integrity. In BRCA1-defective HCC1937 breast cancer cells, COH29 induced more double-strand breaks (DSBs) and DNA-damage response than in HCC1937 + BRCA1 cells. By EJ5- and DR-green fluorescent protein (GFP) reporter assay, we found that COH29 could inhibit nonhomologous end joining (NHEJ) efficiency and that no HR activity was detected in HCC1937 cells, suggesting that repression of the NHEJ repair pathway may be involved in COH29-induced DSBs in BRCA1-deficient HCC1937 cells. Furthermore, we observed an accumulation of nuclear Rad51 foci in COH29-treated HCC1937 + BRCA1 cells, suggesting that BRCA1 plays a crucial role in repairing and recovering drug-induced DNA damage by recruiting Rad51 to damage sites. In summary, we describe here additional biologic effects of the RNR inhibitor COH29 that potentially strengthen its use as an anticancer agent.

UR - http://www.scopus.com/inward/record.url?scp=84940054160&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84940054160&partnerID=8YFLogxK

U2 - 10.1124/mol.114.094987

DO - 10.1124/mol.114.094987

M3 - Article

C2 - 25814515

AN - SCOPUS:84940054160

VL - 87

SP - 996

EP - 1005

JO - Molecular Pharmacology

JF - Molecular Pharmacology

SN - 0026-895X

IS - 6

ER -